- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03777514
Intravenous (IV) Versus Oral Iron Treatment of Iron Deficiency Anemia in the Post-operative Bariatric Surgical Patient
A Randomized, Placebo-controlled Comparator Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-operative Bariatric Surgical Patient
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Rationale for study: The preponderance of published evidence reports superior efficacy and decreased toxicity of intravenous iron compared to oral iron in correcting anemia and iron parameters in published trials of bariatric surgery patients. Intravenous, and not oral, iron ensures adequate delivery and avoids gastrointestinal toxicities, which may be especially burdensome in these patients who require optimal levels of energy to maintain prudent exercise programs recommended by patients' bariatric practitioners. Uncontradicted published evidence reports safety and efficacy of complete replacement doses of intravenous iron administered in one or two doses of either low molecular weight iron dextran, ferumoxytol, ferric carboxymaltose or iron isomaltoside. A common feature of all studies extant is the lack of reported serious adverse events. Even in patients with minimally invasive procedures such as gastric banding or stapling in whom oral iron may be tolerated, given the often present multiple gastrointestinal perturbations, intravenous iron may simplify care.
Drugs used: The investigators propose to use and FDA approved IV iron preparation - ferumoxytol, administered as two doses (over a interval of 2 to 7 days), each 510 mg over fifteen minutes based on published prospective safety and efficacy data and compare the effectiveness of the treatment to the American Metabolic and Bariatric Associations recommended treatment for iron deficiency anemia in the post-operative bariatric patients of oral iron ferrous sulphate 325 mg twice daily for 6 weeks.
Study Type
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged ≥ 18 years
- Patients who have undergone a Roux-en Y Gastric Bypass or Vertical Sleeve Gastrectomy and are at least 3 months or more out from surgery.
- Iron deficiency anemia defined as iron deficient with either ferritin < 20 mcg/l, transferrin saturation (TSAT) < 19%, or anemia with Hgb < 13 g/dL for both males and females.
- Willingness to use contraceptive to avoid pregnancy: Women have to be surgically sterile, post menopausal or use one of the following contraceptives during the whole study period and after the study has ended for at least five times the plasma biological half-life of the investigational medicinal product: intrauterine devices or hormonal contraceptives (contraceptive pills, implants, transdermal patches, hormonal vaginal devices, or injections with prolonged release).
- Willingness to participate and signing the informed consent form.
Exclusion Criteria:
- Iron overload or disturbances in utilization of iron (e.g. hemochromatosis and hemosiderosis)
- Decompensated liver cirrhosis or active hepatitis (ALT > 3 times upper limit of normal)
- Serum ferritin > 500 ng/mL or transferrin saturation > 40%
- Active acute or chronic infections (assessed by clinical judgment that may be indicated by White Blood Cells (WBC) and C-Reactive Protein (CRP) when these are available)
- Rheumatoid arthritis with symptoms or signs of active inflammation
- Pregnant and nursing women
- History of multiple allergies
- Known hypersensitivity to ferumoxytol or oral iron or any excipients in the drug products
- Previous IV iron treatment for IDA
- Other iron treatment or blood transfusion within 4 weeks prior to the screening or treatment visit
- Planned elective surgery during the study
- Any other medical condition that, in the opinion of Investigator, may cause the subject to be unsuitable for the completion of the study or place the subject at potential risk from being in the study, e.g. a malignancy, uncontrolled hypertension, unstable ischemic heart disease, or uncontrolled diabetes mellitus
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: IV iron
Ferumoxytol intravenous (IV) 1020 mg as - 2 vials of 510 mg (510 mg IV over 15 minutes) each given 2-7 days apart. Participants in this group will also receive oral vitamin C as a placebo. |
treatment of iron deficiency anemia with IV iron.
Oral vitamin C to be used as a placebo for participants receiving IV iron
|
Active Comparator: oral iron
Ferrous sulfate 325 mg (oral) tabs morning and evening.
Participants in this group will also receive intravenous normal saline as a placebo.
|
treatment of iron deficiency anemia with oral iron
Intravenous normal saline will be used as placebo for participants receiving oral iron
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Resolution of anemia in oral vs. IV iron as assessed by Clinical Global Impression (CGI) - 2 score
Time Frame: 6 weeks
|
The CGI-2 is a one-item questionnaire which asks how participants feel now compared to before receiving treatment.
It has a scoring of 1 to 7 with 1 meaning much better and 7 meaning very much worse
|
6 weeks
|
Resolution of anemia in oral vs. IV iron as assessed by ferritin level
Time Frame: 6 weeks
|
Participants will be assessed after six weeks to see if there is a resolution of anemia following the treatment with oral or IV iron.
This will be determined by the ferritin level.
Ferritin > 20% will be the cutoff for resolution of anemia.
|
6 weeks
|
Resolution of anemia in oral vs. IV iron as assessed by TSAT
Time Frame: 6 weeks
|
Participants will be assessed after six weeks to see if there is a resolution of anemia following the treatment with oral or IV iron.
This will be determined by TSAT level.
TSAT > 19% will be the cutoff for resolution of anemia.
|
6 weeks
|
Time (weeks) to treatment response as assessed by CGI-2 score
Time Frame: 6 weeks
|
The CGI-2 is a one-item questionnaire which asks how participants feel now compared to before receiving treatment.
It has a scoring of 1 to 7 with 1 meaning much better and 7 meaning very much worse.
This will be used in assessing the time in weeks when participant noticed a change after receiving treatment.
|
6 weeks
|
Time (weeks) to treatment response as assessed by ferritin level
Time Frame: 6 weeks
|
Participants will be assessed after six weeks to identify what time (in weeks) ferritin level was > 20% following the treatment with oral or IV iron
|
6 weeks
|
Time (weeks) to treatment response as assessed by TSAT
Time Frame: 6 weeks
|
Participants will be assessed after six weeks to identify what time (in weeks) TSAT level was > 19% following the treatment with oral or IV iron
|
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Need for continued treatment as assessed by ferritin level
Time Frame: 1 year
|
Participants will be assessed after a year to see if participants require continued treatment following the treatment with oral or IV iron.
This will be determined by the ferritin level.
Ferritin > 20% will be the cutoff for no further need for treatment.
|
1 year
|
Need for continued treatment as assessed by TSAT
Time Frame: 1 year
|
Participants will be assessed after a year to see if participants require continued treatment following the treatment with oral or IV iron.
This will be determined by TSAT level.
TSAT > 19% will be the cutoff for no further need for treatment.
|
1 year
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Kimberley E Steele, MD, Ph.D, Johns Hopkins University
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Metabolic Diseases
- Hematologic Diseases
- Anemia, Hypochromic
- Anemia
- Iron Metabolism Disorders
- Anemia, Iron-Deficiency
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Protective Agents
- Micronutrients
- Vitamins
- Antioxidants
- Hematinics
- Pharmaceutical Solutions
- Parenteral Nutrition Solutions
- Ferrosoferric Oxide
- Ascorbic Acid
Other Study ID Numbers
- IRB00198735
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on IDA in the Post-bariatric Surgical Patient
-
Hospices Civils de LyonCompleted
-
Royal Marsden NHS Foundation TrustUnknownPatient Satisfaction in the Critical Care UnitUnited Kingdom
-
Herlev HospitalCompletedSurgical Behaviour in the Operating RoomDenmark
-
Centre Hospitalier Universitaire DijonCompletedPatient Requiring Scheduled Conventional Orthopedic Surgical Intervention of the Upper or Lower LimbFrance
-
National University Hospital, SingaporeUnknownFocus : To Study the Differences in Patient Compliance to Immunosuppressive Treatments and Patient Preference.Singapore
-
waleed mohammad sabryRecruitingthe Clinical Effect of Surgical Tube Technique in Reconstruction of the Interproximal PapillaEgypt
-
Sheikh Zayed Medical CollegeRecruitingPain Relief in Post Operative PatientPakistan
-
EarlySense Ltd.WithdrawnPost Operative Patient | Patients Requiring PCA | Respiratory Patients | Patients in Risk of FallUnited States
-
Universidad Complutense de MadridCompletedPatients in Need of Surgical CL in the Anterior Maxillary Sextant for Restorative Purposes
-
Famirea Study GroupTerminatedFamily of Dying Patient in the ICU
Clinical Trials on Ferumoxytol
-
Michael IvNational Cancer Institute (NCI)WithdrawnChildhood Brain NeoplasmUnited States
-
Allegheny Singer Research Institute (also known...Active, not recruitingLiver Neoplasms | Hepatocellular Carcinoma | Liver Metastases | Liver Cancer | Liver Carcinoma | Hepatocellular Cancer | Hepatic Cirrhosis | Hepatic Carcinoma | Hepatic AtrophyUnited States
-
Massachusetts General HospitalCompletedPapillary Carcinoma of Thyroid Gland | Metastatic Medullary Thyroid Cancer | Follicular Thyroid Cancer Lymph Node MetastasisUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science University; Radiological Society of North AmericaTerminatedStage III Rectal Cancer AJCC v7 | Stage IIIA Rectal Cancer AJCC v7 | Stage IIIB Rectal Cancer AJCC v7 | Stage IIIC Rectal Cancer AJCC v7 | Locally Advanced Rectal CarcinomaUnited States
-
OHSU Knight Cancer InstituteNational Cancer Institute (NCI); Oregon Health and Science University; National... and other collaboratorsRecruitingPancreatic Adenocarcinoma | Familial Pancreatic Cancer | Pancreatic Intraductal Papillary-Mucinous NeoplasmUnited States
-
Michael IvCompletedBrain Injury | Brain Cancer | Brain Tumors | Primary Brain Neoplasm | Ischemic Cerebrovascular Accident | Central Nervous System Degenerative Disorder | Central Nervous System Infectious Disorder | Central Nervous System Vascular Malformation | Hemorrhagic Cerebrovascular AccidentUnited States
-
Dana-Farber Cancer InstituteWithdrawn
-
AMAG Pharmaceuticals, Inc.UnknownPeripheral Arterial Disease (PAD)United States
-
National Cancer Institute (NCI)CompletedProstate CancerUnited States
-
University of EdinburghRoyal Brompton & Harefield NHS Foundation Trust; Royal Infirmary of Edinburgh; Golden Jubilee National HospitalCompletedMyocarditis | Healthy Volunteers | Cardiac Transplant | Cardiac SarcoidUnited Kingdom